KFAS
DYN icon

Keating Financial Advisory Services’s Dyne Therapeutics DYN Stock Holding History

Keating Financial Advisory Services’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
5,112
+19
+0.4% +$353 0.01% 458
2026
Q1 		$92.3K Buy
5,093
+93
+2% +$1.6K 0.01% 479
2025
Q4 		$97.8K Buy
+5,000
New +$94.7K 0.01% 494

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Keating Financial Advisory Services's DYN Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Dyne Therapeutics (DYN) stake by 0.37% in Q2 2026, buying an estimated $353 and bringing the position to 5,112 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #458.

Keating Financial Advisory Services first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Keating Financial Advisory Services held 5,112 shares of Dyne Therapeutics worth $114K as of Q2 2026.
  • Keating Financial Advisory Services bought 19 Dyne Therapeutics shares in Q2 2026, an estimated $353.
  • Dyne Therapeutics made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #458 holding.
  • Keating Financial Advisory Services first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.